CPC1

TgCPC1 is a cathepsin C dipeptidyl exopeptidase of Toxoplasma gondii that removes dipeptides from unblocked N-terminal substrates and functions in the parasite's secretory and endolysosomal pathway to process invasion/egress effectors (PMID:17164247, PMID:37326431). Within tachyzoites it localizes to the endosome-like compartment (ELC), where it mediates the final trimming of micronemal effectors; its deletion completely blocks activation of the surface subtilisin-like protease TgSUB1, globally impairing effector maturation and producing defects in invasion, egress, and migration (PMID:37326431). TgCPC1 also traffics through dense granules to the parasitophorous vacuole, where it and its paralog TgCPC2 degrade peptides; loss of TgCPC1 alone is phenotypically buffered by compensatory upregulation of TgCPC2 (PMID:17164247). Beyond its parasite-intrinsic protease role, CPC1 protein can act in host cells to suppress NF-κB activation at or downstream of p65 through positive regulation of the HIF-1α/EPO axis, dampening pro-inflammatory cytokine production (PMID:31004564). TgCPC1 is resistant to a chemical inhibitor active against its malarial ortholog, indicating structural divergence among apicomplexan cathepsin C enzymes (PMID:37326431).

1. 2006 High

   Established TgCPC1's enzymatic identity and cellular role: whether the parasite encodes a functional dipeptidyl exopeptidase and where it acts was unknown, and this showed it is a cathepsin C required for peptide degradation in the parasitophorous vacuole.

   Evidence Targeted gene disruption, cathepsin C inhibitor (Gly-Phe-dimethylketone), transgenic beta-lactamase reporter in the parasitophorous vacuole, and dense-granule immunolocalization in tachyzoites

   PMID:17164247

   Open questions at the time

   • Physiological substrates beyond the reporter not identified
   • Mechanism of trafficking to dense granules not defined
2. 2006 Medium

   Addressed why TgCPC1 loss is tolerated: knockout did not impair invasion or growth because the paralog TgCPC2 was upregulated and could substitute, revealing functional redundancy.

   Evidence TgCPC1 knockout with intracellular growth/invasion assays and real-time PCR of TgCPC2 expression

   PMID:17164247

   Open questions at the time

   • Direct proof of TgCPC2 functional substitution (rescue) not shown
   • Whether double knockout is lethal untested
3. 2008 Medium

   Corroborated the dense-granule/parasitophorous vacuole trafficking route for TgCPC1 and TgCPC2 in a second study.

   Evidence Subcellular fractionation/immunolocalization referenced from prior characterization

   PMID:19111576

   Open questions at the time

   • Referenced rather than newly generated data
   • Does not define the sorting signals or machinery
4. 2019 Medium

   Extended CPC1's role to host-directed immune modulation: it was unknown whether the protein influences host inflammation, and this showed it suppresses NF-κB at or downstream of p65 via the HIF-1α/EPO axis.

   Evidence Overexpression/knockdown of CPC1, phospho-p65 western blot, HIF-1α/NF-κB dual-luciferase reporters, RNA-seq, cytokine measurements, and EPO/HIF-1α knockdown epistasis; CPC1 detected in host cell cytoplasm

   PMID:31004564

   Open questions at the time

   • Direct molecular target linking CPC1 protease activity to HIF-1α/EPO not identified
   • Cytoplasmic host localization mechanism unexplained
   • Whether the exopeptidase activity is required for NF-κB suppression untested
5. 2023 High

   Redefined TgCPC1's core parasite function: it localizes to the endosome-like compartment and its deletion completely blocks TgSUB1 activation, placing it upstream of surface effector maturation and explaining invasion, egress, and migration defects.

   Evidence Genetic deletion, ELC immunolocalization, invasion/egress/migration assays, and western blot analysis of micronemal protein maturation and TgSUB1 activation

   PMID:37326431

   Open questions at the time

   • Direct enzyme-substrate relationship between TgCPC1 and TgSUB1 propeptide not demonstrated
   • Reconciliation of ELC vs. dense-granule/PV localization not resolved
   • Full effector substrate set not enumerated
6. 2023 Medium

   Demonstrated pharmacological divergence: TgCPC1 resists an inhibitor of its malarial ortholog, indicating structural differences relevant to species-selective drug targeting.

   Evidence Pharmacological inhibitor assay comparing TgCPC1 against a malarial CPC inhibitor

   PMID:37326431

   Open questions at the time

   • No structural model of TgCPC1 provided
   • Basis of inhibitor resistance at the active site not defined

• How TgCPC1's ELC-localized protease activity mechanistically triggers TgSUB1 activation, and how this parasite-intrinsic role integrates with the reported host cytoplasmic NF-κB suppression, remain unresolved.
• No direct biochemical demonstration of TgSUB1 propeptide processing by TgCPC1
• Localization discrepancies (ELC vs. dense granule/PV vs. host cytoplasm) unreconciled
• No structural characterization